Business Description
Medifron DBT Co Ltd
ISIN : KR7065650004
Compare
Compare
Traded in other countries / regions
065650.Korea IPO Date
2003-01-21Description
Medifron DBT Co Ltd is a Korean clinical stage biopharmaceutical company. The company is focused on the development of Alzheimer's disease (AD) and neuropathic pain (NP) treatment and AD diagnostics.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 2.88 | |||||
| Equity-to-Asset | 0.66 | |||||
| Debt-to-Equity | 0.15 | |||||
| Debt-to-EBITDA | -14.55 | |||||
| Piotroski F-Score | 4/9 | |||||
| Altman Z-Score | 1.98 | |||||
| Beneish M-Score | -0.7 | |||||
| WACC vs ROIC | ||||||
Growth Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 5.9 | |||||
| 3-Year EBITDA Growth Rate | 45.5 | |||||
| 3-Year EPS without NRI Growth Rate | 35 | |||||
| 3-Year FCF Growth Rate | 16 | |||||
| 3-Year Book Growth Rate | -1.6 |
Momentum Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 83.4 | |||||
| 9-Day RSI | 67.62 | |||||
| 14-Day RSI | 60.94 | |||||
| 6-1 Month Momentum % | 50.8 | |||||
| 12-1 Month Momentum % | 17.44 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 1.85 | |||||
| Quick Ratio | 1.78 | |||||
| Cash Ratio | 0.92 | |||||
| Days Inventory | 32.65 | |||||
| Days Sales Outstanding | 49.25 | |||||
| Days Payable | 8.74 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -11.6 | |||||
| Shareholder Yield % | 0.8 |
Profitability Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 16.13 | |||||
| Operating Margin % | -2.59 | |||||
| Net Margin % | -3.77 | |||||
| FCF Margin % | -4.81 | |||||
| ROE % | -6.63 | |||||
| ROA % | -3.48 | |||||
| ROIC % | -4.22 | |||||
| ROC (Joel Greenblatt) % | -10.37 | |||||
| ROCE % | -2.64 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio without NRI | 43.65 | |||||
| PEG Ratio | 3.8 | |||||
| PS Ratio | 0.15 | |||||
| PB Ratio | 2.03 | |||||
| Price-to-Tangible-Book | 2.05 | |||||
| EV-to-EBIT | -50.58 | |||||
| EV-to-EBITDA | -171.27 | |||||
| EV-to-Revenue | 1.24 | |||||
| EV-to-FCF | -25.76 | |||||
| Price-to-Median-PS-Value | 0.01 | |||||
| Price-to-Net-Current-Asset-Value | 5.76 | |||||
| Earnings Yield (Greenblatt) % | -1.98 | |||||
| FCF Yield % | -3.35 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Medifron DBT Co Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil â‚©) | 52,042.006 | ||
| EPS (TTM) (â‚©) | -23 | ||
| Beta | 1.66 | ||
| Volatility % | 57.42 | ||
| 14-Day RSI | 60.94 | ||
| 14-Day ATR (â‚©) | 83.70184 | ||
| 20-Day SMA (â‚©) | 1373.1 | ||
| 12-1 Month Momentum % | 17.44 | ||
| 52-Week Range (â‚©) | 920 - 2565 | ||
| Shares Outstanding (Mil) | 51.74 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Medifron DBT Co Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Medifron DBT Co Ltd Stock Events
| Event | Date | Price(â‚©) | ||
|---|---|---|---|---|
| No Event Data | ||||
Medifron DBT Co Ltd Frequently Asked Questions
What is Medifron DBT Co Ltd(XKRX:065650)'s stock price today?
The current price of XKRX:065650 is â‚©1445.00. The 52 week high of XKRX:065650 is â‚©2565.00 and 52 week low is â‚©920.00.
When is next earnings date of Medifron DBT Co Ltd(XKRX:065650)?
The next earnings date of Medifron DBT Co Ltd(XKRX:065650) is .
Does Medifron DBT Co Ltd(XKRX:065650) pay dividends? If so, how much?
Medifron DBT Co Ltd(XKRX:065650) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers